DC0-NH2

• Description:

  DC0-NH2 is an effector moiety for ADC and a simplified analog of DC1 with better stability. DC0-NH2 is about 1000-fold more cytotoxic than commonly used anticancer agents (ex. Doxorubicin) . DC0-NH2 can bind to the minor groove of DNA, followed by alkylation of adenine residues by its propabenzindole (CBI) component[1].

• UNSPSC:

  12352203

• Target:

  ADC Payload

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/dc0-nh2.html

• Purity:

  95.00

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  O=C(C(N1)=CC2=C1C=CC(N)=C2)NC3=CC4=C(NC(C(N5C[C@@H](CCl)C6=C5C=C(O)C7=CC=CC=C67)=O)=C4)C=C3

• Molecular Formula:

  C31H24ClN5O3

• Molecular Weight:

  550.01

• References & Citations:

  [1]Zhao RY, et al. Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer.J Med Chem. 2012 Jan 26;55 (2) :766-82.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, stored under nitrogen)

• Scientific Category:

  ADC Related

• Clinical Information:

  No Development Reported

• Isoform:

  Duocarmycins

• CAS Number:

  615538-51-7